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A B S T R A C T
Magnetic resonance imaging (MRI) volumetric measures have become a standard tool for the detection of in-
cipient Alzheimer's Disease (AD) dementia in mild cognitive impairment (MCI). Focused on providing an earlier
and more accurate diagnosis, sophisticated MRI machine learning algorithms have been developed over the
recent years, most of them learning their non-disease patterns from MCI that remained stable over 2–3 years. In
this work, we analyzed whether these stable MCI over short-term periods are actually appropriate training
examples of non-disease patterns. To this aim, we compared the diagnosis of MCI patients at 2 and 5 years of
follow-up and investigated its impact on the predictive performance of baseline volumetric MRI measures pri-
marily involved in AD, i.e., hippocampal and entorhinal cortex volumes. Predictive power was evaluated in
terms of the area under the ROC curve (AUC), sensitivity, and specificity in a trial sample of 248 MCI patients
followed-up over 5 years. We further compared the sensitivity in those MCI that converted before 2 years and
those that converted after 2 years. Our results indicate that 23% of the stable MCI at 2 years progressed in the
next three years and that MRI volumetric measures are good predictors of conversion to AD dementia even at the
mid-term, showing a better specificity and AUC as follow-up time increases. The combination of hippocampus
and entorhinal cortex yielded an AUC that was significantly higher for the 5-year follow-up (AUC=73% at
2 years vs. AUC=84% at 5 years), as well as for specificity (56% vs. 71%). Sensitivity showed a non-significant
slight decrease (81% vs. 78%). Remarkably, the performance of this model was comparable to machine learning
models at the same follow-up times. MRI correctly identified most of the patients that converted after 2 years
(with sensitivity> 60%), and these patients showed a similar degree of abnormalities to those that converted
before 2 years. This implies that most of the MCI patients that remained stable over short periods and subse-
quently progressed to AD dementia had evident atrophies at baseline. Therefore, machine learning models that
use these patients to learn non-disease patterns are including an important fraction of patients with evident
pathological changes related to the disease, something that might result in reduced performance and lack of
biological interpretability.
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Alzheimer's disease (AD), the most common form of dementia in the
elderly population, is still presenting challenges for an early diagnosis.
Since the only definite way to identify AD is by means of a brain biopsy,
this disease is predominantly diagnosed clinically (McKhann et al.,
2011) and, when possible, diagnosis is supported with biomarkers de-
rived from cerebrospinal fluid or imaging. Although certainty in diag-
nosis augments by tracking the progression in time of cognitive per-
formance, early symptoms of AD are difficult to distinguish from age-
related cognitive impairment and other neuropsychological disorders.
These early symptoms are common to a condition known as mild cog-
nitive impairment (MCI) (Petersen et al., 1999) in which a cognitive
decline is evident but not sufficiently specific to be considered incipient
AD. At this stage, the mean annual conversion rate from MCI to prob-
able AD is about 7%, with most of the MCI patients not progressing to
AD within 10 years (Mitchell and Shiri-Feshki, 2009). This result sug-
gests that the origin of the MCI condition is variable and cannot be only
attributed to AD, making difficult to filter out those MCI patients with
incipient AD.
As pointed out in Greenberg et al. (2013)), a possible reason of the
failure of some clinical trials could be the selection of participants with
clinical AD at a disease stage that might be too progressed to benefit
from the treatment. Restricting the selection to MCI participants
seemed the most straightforward solution to this issue. However, the
aforementioned heterogeneity of MCI, both in definition and etiology,
along with low conversion rates, critically contributed to the im-
possibility of detecting differences between treatment and placebo
groups (Schneider et al., 2014). Furthermore, in order to be approved as
a clinical target, both the US Food and Drug Administration (FDA) and
the European Medicines Agency (EMA) stated that MCI must be defined
through robust and validated criteria, being the EMA even more re-
strictive by requiring positivity in at least one biomarker of amyloidosis
or neurodegeneration (Drug Administration Peripheral and Central
Nervous System Drugs Advisory Committee, 2001; European medicines
agency. pre-authorisation evaluation of medicines for human use,
2008). These requirements resulted in clinicopathological diagnostic
definitions, known as prodromal AD or MCI due to AD (Dubois et al.,
2007; Albert et al., 2011), incorporating biomarkers. These definitions
are widely used nowadays in clinical trials of disease-modifying drugs
(Cummings et al., 2017).
Among biomarkers of AD, structural Magnetic Resonance Imaging
(MRI) is the most commonly used technique to identify brain atrophies
related to AD. Hippocampal atrophy, i.e., volumetric abnormality, as-
sessed visually or quantitatively, is the best established MRI biomarker
of AD (Hill et al., 2014), although there is accumulating evidence that
atrophies in other parts of the brain such as the entorhinal cortex
provide complementary prognostic information as well (Killiany et al.,
2002; Du et al., 2001; Dickerson et al., 2001; Devanand et al., 2012;
Devanand et al., 2007). Beyond visual assessment and volumetric
measurements, several different machine learning approaches have
been explored for both feature extraction and classification, reporting
an earlier and better detection of AD standard metrics (Rathore et al.,
2017). Although the most emphasized strength of these approaches is
the power to predict AD dementia earlier, a few models were also de-
signed with the aim of predicting imminent conversion, so that clinical
trials could use these approaches for sample enrichment. Despite the
good reported results, these techniques have not been used yet either in
clinical routine nor trials (Rathore et al., 2017; Arbabshirani et al.,
2017), probably due to poor performance when evaluated in new data
sets (Arbabshirani et al., 2017). As an example, in (Cuingnet et al.,
2011), 10 methods that reported significant prognostic ability using
MRI were evaluated using new data. None of them showed to be dif-
ferent from random chance, indicating that the previously reported
results were probably biased. Experimenter interventions in the testing
process, tuning some of the free parameters of the model, and circular
analysis or double-dipping (Kriegeskorte et al., 2009) might explain the
lack of generalizability of these models.
Apart from the previously mentioned methodological issues, we also
found issues concerning the training sample. The typical approach
when training a machine learning classifier is to label as progressive
MCI (pMCI) those MCI patients who converted to AD within a fixed
follow-up time, typically 1–3 years, and to label as stable MCI (sMCI)
those who have not converted within that period. Using this labeling,
machine learning algorithms learn the pattern that, theoretically, best
discriminates between incipient AD and the rest of MCI. The conceptual
validity of this approach relies on the assumption that only a negligible
fraction of the sMCI patients are affected by AD or, alternatively, those
sMCI actually affected by AD present a too early disease stage in which
no major structural changes have occurred yet. Based on the latter as-
sumption, an important number of machine learning classifiers were
trained to capture the subtle structural changes that may contribute to
an earlier prediction of AD (Rathore et al., 2017). However, neither the
hypothesis of the absence of evident structural changes in mid-term
pMCI nor the small size of its effect have been confirmed yet, leaving
unclear how accurate is the correspondence between sMCI and absence
of AD. If an important deviation of this correspondence is finally con-
firmed, it would imply that this common labeling suffers from poor
biological interpretability and, therefore, may result in reduced per-
formance and lack of generalizability.
In this work, we studied the predictive power of MRI measurements
of hippocampal and entorhinal cortex volumes for short (2 years) and
mid-term (5 years) follow-up times. We also investigated the perfor-
mance in the subgroups of MCI who converted before 2 years (short-
term pMCI), and in those who converted after 2 years and before 5
(mid-term pMCI), as well as in sMCI over 5 years versus sMCI with
shorter follow-up times. To this aim, we used all the available data from
the ADNI database, including data from (Petersen et al., 1999) MCI
patients enrolled in ADNI1 and ADNI2. To our knowledge, this is the
first study in which the predictive power of MRI is evaluated at 5-year
follow-up using the ADNI1 and ADNI2 MCI cohorts, providing a de-
tailed comparison of performance between the short and mid-term.
2. Materials and methods
2.1. Data
Data used in the preparation of this article were obtained from the
Alzheimer's Disease Neuroimaging Initiative (ADNI) database http://
adni.loni.usc.edu. The ADNI was launched in 2003 as a public-
private partnership, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether serial MRI, PET,
other biological markers, and clinical and neuropsychological assess-
ment can be combined to measure the progression of MCI and early AD.
The ADNI project comprises 4 different studies, namely the com-
pleted ADNI1, ADNIGO and ADNI2, and the ongoing ADNI3, launched
in September 2016. Among the completed studies, ADNI1 and ADNI2
recruited the majority of the participants while ADNIGO recruited only
early MCI participants and its main purpose was to serve as a con-
tinuation of ADNI1.
2.2. MRI
ADNI2 used only 3 T scanners while ADNI1 employed different
protocols and acquired images using 1.5 T scanners, although a small
fraction of participants was rescanned with 3 T devices. We restricted to
the 1.5 T scan for ADNI1 participants. A detailed MRI acquisition pro-
tocol of the different studies of the ADNI project can be found at
http://adni.loni.usc.edu/methods/documents/. The ADNI
collaborators at the Center for Imaging of Neurodegnerative Diseases at
University of California, San Francisco (UCSF) provided Freesurfer
(version 4.3 in ADNI1 and 5.1 in ADNI2) (Fischl, 2012) segmentations
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of MRI T1 images from ADNI participants. Quality of the segmentations
was assessed by the researchers at UCSF to ensure a correct parcellation
of the brain. A detailed description of the quality control process can be
found at http://adni.loni.usc.edu/data-samples/access-data/. The most
common failures occur at the cortical level. About 69% of the seg-
mentations in ADNI passed the entire quality control. In this study, only
segmentations that fulfilled all the quality criteria were included.
Among the available images for each patient, only non-accelerated
MPRAGE or IR-SPGR sequences were used. Cortical segmentation was
performed using the Desikan-Killiany Atlas (Desikan et al., 2006).
Subcortical segmentation scheme was the same as the one described in
(Filipek et al., 1994). For simplicity, only total volumes (left plus right)
of the hippocampus and entorhinal cortex were considered in this
study. We estimated the total intracranial volume (TIV) with SPM12
(Penny et al., 2011) using the utility ‘Tissue Volumes’ (Malone et al.,
2015). We provided the Image IDs, as well as the computed TIVs, in the
Supplementary Material.
2.3. Subjects
We only included patients from the following diagnostic groups in
the ADNI1/2 study: Normal Controls (NC), late MCI (MCI) and AD.
Patients in the diagnostic group of Subjective Memory Complaints
(SMC) or early MCI were not included. We did not include Early MCI
because the aim of this study is to compare the performance of well-
known volumetric biomarker metrics with the performance of state-of-
the-art machine learning models, which, to the best of our knowledge,
were mainly applied to late MCI data (Rathore et al., 2017;
Arbabshirani et al., 2017). The inclusion criteria of the diagnostic
groups in the ADNI1/GO/2 study can be found at http://adni.
loni.usc.edu/methods/documents/. All the participants without
clinical evaluation at baseline were excluded. We selected all the par-
ticipants with available segmentations that passed the quality control.
Only MCI patients with a suspected MCI due to Alzheimer's disease at
baseline were included. We excluded all the MCI participants that re-
mained stable and withdrew before the minimum follow-up considered
in this study, 2 years. MCI patients were considered progressive MCI
(pMCI) if they converted at any point within the follow-up time, re-
gardless of the observed outcome in longer follow-up times. For these
pMCI patients, conversion time was estimated as the mid-point between
the visit in which AD is diagnosed for the first time and the previous
visit. MCI patients who progressed to other types of dementia were
regarded as stable MCI (sMCI). We also excluded NC participants in
which a progression to MCI or AD was observed at any point in their
follow-up, as well as AD patients in which a reversion to MCI or NC
occurred. After this selection, the number of NC participants was su-
perior to AD in both ADNI1 and ADNI2 cohorts. In order to obtain a
balanced sample of NC and AD in both ADNI studies, we excluded those
participants with the shortest follow-up times until we balanced the
number of NC and AD. We chose a balanced design to exclude in-
formative prior probability (Chawla et al., 2004). Fig. 1 shows a sche-
matic diagram of the whole selection process.
It should be noted that the inclusion criteria for all the previously
mentioned diagnostic categories are equivalent across ADNI1/2, the
only difference being that ADNI2 required a lumbar puncture to par-
ticipate in the study. Thus, and given the differences in imaging pro-
tocols, we decided to analyze ADNI1 and ADNI2 MRI data of common
diagnostic cohorts (NC, MCI, and AD) separately. RID identification
numbers and diagnosis for the different follow-up times were provided
in the Supplementary Material.
2.4. Performance evaluation
In order to obtain an index for the prediction of MCI progression
based on baseline MRI data, we fitted logistic regressions on each NC
vs. AD sample from ADNI1 (1.5 T) and ADNI2 (3 T). We fitted three
models with different inputs, i.e., using hippocampal volume alone,
using entorhinal cortex volume alone, and using hippocampal and en-
torhinal cortex volumes (MRI model). All the inputs were measured at
baseline. The models included Age and TIV to account for aging and
cranial size (model equations are provided in the Supplementary
Material). To derive classification cut points, we followed the re-
commendations of (Neurobiol. Aging, 1998) and established a cut point
in which a sensitivity of 85% in identifying AD patients was obtained
(the derived cut-points are reported in the Supplementary Material).
Logit values were used as predictive indexes in the trial MCI cohort.
Note that this approach is completely bias-free since the MCI cohort did
not play any role when training the models.
The first analysis was carried out to compare the predictive per-
formance of MRI as a function of follow-up time from short (2 years) to
mid-term (5 years) follow-up times, in annual steps. We computed the
area under the Receiver Operating Characteristic Curve (AUC), sensi-
tivity (proportion of pMCI correctly classified) and specificity (pro-
portion of sMCI correctly classified).
We also performed three different subgroup analyses to evaluate
how conversion time and time remaining stable affected classification
accuracy of MRI. Specifically, in Subanalysis 1 we compared sensitiv-
ities in short-term pMCI (converters within 2 years) and mid-term pMCI
(converters after 2 years and before 5) to investigate how NC-like pa-
tients at baseline that then progressed within 5 years affect the overall
sensitivity. In Subanalysis 2 we stratified the sMCI patients over 2 years
into those that remained stable for 5 years and those with shorter
follow-up times. We then compared specificities between these two
independent samples, so we can assess that our results are not influ-
enced due to the exclusion of sMCI that did not reach the 5 year end-
point. In Subanalysis 3, we separated converters into short-term and
mid-term converters, as in Subanalysis 1. We then computed the AUCs
of these two types of converters versus sMCI over 5 years, and com-
pared the results. In this way, we can evaluate whether short-term and
mid-term converter distributions of atrophies present different degrees
of overlapping with the distribution of sMCI over five years. A sche-
matic summary of the subanalyses can ben seen in Fig. 2.
2.5. Statistical analysis
95% confidence intervals (CI) for AUC, sensitivity, and specificity
were calculated using Clopper-Pearson confidence intervals. As pre-
viously mentioned, ADNI1 and ADNI2 MCI cohorts followed slightly
different inclusion and imaging criteria. Therefore, we pooled AUC,
sensitivity, and specificity of these two studies, as well as estimated
confidence intervals, following a fixed effects model with a Freeman-
Tukey transformation (Freeman and Tukey, 1950). The standard de-
viations used for pooling AUCs were computed according to the DeLong
method (DeLong et al., 1988).
In Subanalyses 1 and 2, we compared sensitivities and specificities
using a chi-square test. No separation between the different studies of
ADNI was done in these tests. We tested that all the classifiers were
significantly different from chance using permutation tests (Ojala and
Garriga, 2010). Significance level was set to α=0.05.
3. Results
3.1. Population
The selection process described in Section 2.3 resulted in a sample
of 230 NC and 230 AD (124 from ADNI1 and 106 from ADNI2). Sample
sizes MCI varied with follow-up time due to withdrawal. Table 1 shows
the number of sMCI and pMCI at 2 and 5 years follow-up. Demographic
information for intermediate follow-up times is provided in Supple-
mentary Table 1. The number of conversions per year can be seen in
Fig. 3 A). Fig. 3 B) shows that 23% of sMCI at 2 years progressed in the
next 3 years. Three MCI converted to other types of dementia and were
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regarded as sMCI. Descriptive statistics of sex, age, MMSE and APOE
status are also provided in Table 1.
3.2. Performance of MRI in the short and mid-term
Fig. 4 shows the results for the prediction of AD dementia in the MCI
cohort as a function of follow-up time. Each model was significantly
different from chance, at every follow-up time and for ADNI1 and
ADNI2 (p < 0.001). Discrimination power between sMCI and pMCI
was stronger for the 5-year follow-up on each model. The best dis-
crimination at the 5-year follow-up was achieved by the MRI model
with an AUC=84%, CI: [78–89], showing an increase of 11% in AUC
compared to the 2-year follow-up (AUC=73%, CI: [68–78]). There
was also a strong rise in specificity, increasing about 14% on each
model while sensitivity slightly decreased for the hippocampus and the
MRI model but increased for the entorhinal cortex. Fig. 4 shows that
this increase in AUC and specificity is the endpoint of a consistent trend
as follow-up time increases. All these trends were observed in ADNI1
and ADNI2 for each model (Supplementary Tables 2 and 6).
In order to test whether patients that withdrew potentially biased
our results, we compared the performance of each model on the 5-year
follow-up set of MCI patients with the performance on that set after
Fig. 1. Diagram showing the selection criteria used in this study.
Fig. 2. Schematic summary of the subanalyses involving different times to conversion and stability.
A. Moscoso, et al. NeuroImage: Clinical 23 (2019) 101837
4
relabeling the diagnosis of MCI patients at the 2-year follow-up
(Table 2). Results were almost identical to those obtained in the pre-
vious analysis.
Subanalysis 1 showed only a significant decrease in classification
accuracy of mid-term pMCI compared to short-term pMCI in the hip-
pocampus model (65%, CI: [50–79] vs. 83%, CI: [76–89], p=0.013),
while entorhinal cortex model increased (80%, CI: [66–90] vs. 77%, CI:
[69–84], p=0.77) and the MRI model decreased (67%, CI: [52–80] vs.
80%, CI: [73–87], p=0.072). Despite this sensitivity degradation in
hippocampus and MRI model, most of the patients were correctly
classified regardless of conversion time, as can be seen in Fig. 5. Sub-
analysis 2 showed that classification accuracy in the sMCI sample with
shorter follow-up times than 5 years was significantly lower than the
corresponding classfication accuracy of sMCI over 5 years, for all the
models, (43%, CI: [34–52] vs. 63%, CI: [51–74], p < 0.01 for hippo-
campus, 40%, CI: [32–49] vs. 66%, CI: [54–77], p < 0.001 for en-
torhinal cortex, and 47%, CI: [38–56] vs. 71%, CI: [60–81], p < 0.001
for the MRI model), and in both ADNI1 and ADNI2 studies (Supple-
mentary Tables 4 and 8). In Subanalysis 3, the AUCs of the MRI model
were similar for both short and mid-term pMCI, (AUC=84%, CI:
[78–90] vs. AUC=82%, CI: [74–90]). AUCs were similarly high for
both types of converters in the rest of the models (Supplementary
Table 12). Detailed results for ADNI1 and ADNI2 were provided in
Supplementary Tables 2–12.
4. Discussion
In this work, we investigated the impact of the extension of follow-
up time from short (2 years) to mid-term (5 years) on the predictive
performance of MRI. Our results were derived using all the available
data from ADNI1 and ADNI2, resulting in 248 MCI trial patients with a
5-year follow-up. This work is, to our knowledge, the first that thor-
oughly investigated the predictive power of MRI beyond the short-term
in a relatively large cohort.
We demonstrated that an extension of follow-up time from 2 to
5 years results in a change in diagnosis of 23% sMCI patients and in
unexpected increases of about 10% and 15% in AUC and specificity,
respectively, in predictive performance. It should be noted that the
increase in AUC is independent from cut-point definition, so the im-
provement cannot be explained due to cut-point selection. This result is
closely related to the similar and high AUCs (> 82%) found in
Subanalysis 3, indicating that mid-term pMCI patients have comparable
atrophies to short-term pMCI. The observation of a significant im-
provement in classification performance when extending follow-up
Table 1
Demographic information of the different samples studied in this work. Suffixes -2y and -5y stand for 2 and 5 year follow-up times, respectively. Age and MMSE Score
are reported as median [range]. Hippocampal and entorhinal cortex volumes represent the average between left and right volumes, expressed as mean ± standard
deviation.
Study Diagnostic group Number Gender
(M/F)






ADNI1 NC 124 62/62 74 [60–90] 29 [25–30] 26/2 3.7 ± 0.4 1.9 ± 0.3
AD 124 65/59 75 [55–90] 23 [20–27] 59/25 2.8 ± 0.5 1.4 ± 0.3
MCI
sMCI-2y 134 85/49 75 [55–88] 28 [24–30] 53/12 3.3 ± 0.5 1.7 ± 0.4
pMCI-2y 89 51/38 75 [56–88] 26 [23−30] 49/15 2.9 ± 0.5 1.5 ± 0.4
sMCI-5y 47 33/14 75 [60–86] 28 [24–30] 17/0 3.5 ± 0.4 1.9 ± 0.3
pMCI-5y 126 72/54 74 [55–88] 27 [23–30] 67/22 3.0 ± 0.5 1.5 ± 0.4
ADNIGO/2 NC 106 50/56 72 [56–85] 30 [24–30] 28/2 3.8 ± 0.5 1.9 ± 0.3
AD 106 57/49 75 [56–90] 23 [19–26] 45/24 3.0 ± 0.5 1.5 ± 0.3
MCI
sMCI-2y 64 34/30 71[55–85] 28 [24–30] 18/7 3.6 ± 0.5 1.8 ± 0.3
pMCI-2y 44 24/20 73 [57–85] 26 [24–30] 23/9 3.0 ± 0.5 1.6 ± 0.4
sMCI-5y 24 13/11 68 [55–85] 29 [25–30] 7/3 3.8 ± 0.5 1.9 ± 0.3
pMCI-5y 51 28/23 73 [57–85] 27 [24–30] 25/10 3.1 ± 0.5 1.6 ± 0.3
Fig. 3. A): Number of conversions per year of MCI patients. B): Proportions of stable MCI that progressed to AD dementia in subsequent years, for each follow-up
time. N indicates the number of stable MCI.
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time in MCI patients can be explained by a more accurate ground-truth
diagnosis of sMCI. In other words, some patients with incipient AD
dementia, presenting measurable pathological features, did not have
enough time to progress to AD dementia due to insufficient follow-up
time. This is supported by Subanalysis 2, showing that specificity in
sMCI at 5 years was significantly higher (71%, CI: [60–81]) than the
corresponding for the rest of the sMCI with shorter follow-up (47%, CI:
[38–56]), and by the fact that most of the mid-term pMCI presented
evident atrophies (Fig. 5). As a result, a significantly lower specificity
and an overall decrease in discriminative power were observed at
2 years follow-up. Although this effect was already known in early-stage
biomarkers such as brain amyloidosis (Buchhave et al., 2012), we
provide first-time evidence that it also matters in a late stage biomarker
such as atrophy in MRI. Regarding the behavior of sensitivity, there are
two competing factors that determine its trend with follow-up time. On
the one hand, atrophy is a late stage pathophysiological change in the
course of AD (Jack Jr and Holtzman, 2013) and, thus, by increasing
follow-up time we provide more time for the development of atrophies
and AD dementia in patients that had no atrophies at baseline. This
effect results in an increased number of false negatives, so we expect
certain decrease in sensitivity as we increase follow-up time. On the
other hand, there is a significant number of patients with atrophies that
only progressed in the mid-term, so these false positive cases turned out
to be true positive, increasing sensitivity. Looking at Fig. 3, it seems that
these two factors compensate each other, resulting in a relatively stable
sensitivity for the follow-up times studied here.
From a clinical perspective, the fact that many atrophied patients do
not progress in the short-term but in subsequent years indicates that
hippocampal and entorhinal atrophy can be ascertained at mid-term
time frames prior to the onset of dementia and that this pathological
feature is more specific than what was previously thought. This finding
can contribute to re-examine the role of hippocampal and entorhinal
atrophy as indicators of short-term decline, reinforcing their early
prognostic ability, and to re-evaluate their importance at the time of
diagnosing early AD dementia. Moreover, the observation of the same
levels of atrophy in patients who progressed in the short-term and in the
mid-term supports the hypothesis that progression depends on more
factors than just biomarker evidence of AD. Among the possible factors,
it is likely that cognitive reserve (Stern, 2012) drives most of the var-
iance in conversion times and, thus, comparing clinical symptoms with
the expected clinical symptoms for the observed atrophy might help to
better predict progression.
Our findings also have implications on the novel machine learning
algorithms that learn discriminative patterns from a sample of sMCI and
pMCI over a short follow-up time. Table 3 presents a summary of the
aforementioned algorithms reviewed in (Rathore et al., 2017) that re-
ported AUC as a performance measure. We selected AUC for being the
most robust performance measure against sample imbalance. They used
a wide variety of methods, some of high complexity, to detect AD de-
mentia in MCI patients, claiming in some cases to be earlier and more
accurate predictors than common volumetric measures. In this context,
it is surprising that a simple model based solely on the hippocampus
and the entorhinal cortex, such as the one studied in this paper, eval-
uated in a larger and independent sample, and in a longer time frame
with conversions to AD dementia after 4 and 5 years from diagnosis,
outperformed in terms of AUC all the complex machine learning
methods. Although the reason for this improvement is simply the more
refined sample of sMCI patients resulting from a longer follow-up or,
equivalently, the good ability to predict mid-term conversion, the
performance of our model at 2 and 3 years of follow-up was comparable
with most of the machine learning methods (Table 3), casting doubt on
the supposed improvement that these methods provide compared to
simple volumetric measures. At short follow-up times, machine learning
algorithms are forced to learn their complex, subtle patterns using a
misleading ground-truth diagnosis in an important proportion of pa-
tients while ignoring evident pathological features such as measurable
hippocampal or entorhinal atrophies, contributing to spoil any biolo-
gical interpretation of the results and making the algorithm a black box
whose behaviour might be unpredictable in new datasets. For instance,
and even if an MRI-only-based ML algorithm is designed with the only
purpose of sample enrichment in clinical trials, we believe that training
on the basis of discriminating converter and stable patients within a
Fig. 4. Area under the ROC curve (AUC), sensitivity and specificity of hippocampus, entorhinal cortex, and MRI model for the prediction of AD dementia in MCI as a
function of follow-up time. Vertical bars represent 95% confidence intervals.
Table 2
Area under the ROC curve (AUC), sensitivity and specificity of each model for the prediction of AD dementia, evaluated on the 5-year follow-up set of MCI patients
and for the diagnosis at 2 and 5 years of follow-up.
Model AUC (%) Sensitivity (%) Specificity (%)
2-year 5-year 2-year 5-year 2-year 5-year
Hippocampus 74 [68–80] 80 [74–86] 83 [76–89] 79 [72–84] 52 [43–61] 63 [51–74]
Entorhinal cortex 69 [63–76] 80 [74–86] 77 [69–84] 78 [71–84] 50 [39–58] 66 [54–77]
MRI model 74 [68–80] 84 [78–89] 86 [79–91] 78 [71–84] 56 [47–66] 71 [60–81]
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short period might present both generalization and interpretation pro-
blems. As mentioned before, inter subject differences in time to pro-
gression to AD dementia in patients with the same level of neurode-
generation are probably explained by differences in cognitive reserve
(Jack Jr and Holtzman, 2013; Stern, 2012). This implies that an im-
portant part of the variance in conversion times is driven by variables
that are independent of MRI and, therefore, variations in these variables
across different populations (more educated cohorts or cultural differ-
ences) will probably affect the performance of the ML model. For in-
stance, consider an ML model which is tested in a cohort that is less
educated than the cohort used to train the model. A higher level of
education implies a higher cognitive reserve (Meng and DArcy, 2012)
and, therefore, we expect that patients progressing within 2 years will
present a more advanced pathophysiological stage, i.e., higher baseline
atrophies than those progressive patients in the less educated cohort.
Thus, the ML model will learn that a very advanced atrophy is neces-
sary to ascertain conversion within 2 years, resulting in an increased
number of false negatives in the less educated test cohort, in which the
level of atrophy required to progress is expected to be lower. This im-
plies that a fraction of patients with evident atrophies will be labeled as
non-progressive, even when these atrophies might be severe and we
will actually observe a progression, spoiling the reliability and inter-
pretability of the model.
Although we consider that the aforementioned issues contribute to
the non-generalizability of machine learning methods in incipient AD
dementia detection (Arbabshirani et al., 2017), we also consider that
they are not the only ones. As stated in Section 1, it is equally important
the report of non-biased results and a statistically powerful comparison
between novel and standard metrics. As an example, the two best-
performing algorithms from Table 3 manually tuned some of the mul-
tiple parameters of their complex algorithms, which may result in op-
timistically biased results. These pitfalls, but also others of a different
nature, were also common in the rest of the algorithms and critically
contribute, in our view, to poor generalizability.
Looking at Table 3, it seems evident that if MRI machine learning
algorithms can actually provide an improvement in AD dementia de-
tection, this improvement has to be relatively small. However, even if
this small improvement exists, this result is going to be impossible to
ascertain due to the uncertainty generated by 20% of sMCI patients who
are misleadingly labeled as non-AD. It is of capital importance to pro-
vide an accurate ground-truth diagnosis in training phases, probably
including only those stable MCI with the longest follow-up times, in
order to exploit the potential of machine learning to improve AD de-
mentia detection in the usually small available cohorts. Although we
explored a relatively long 5-year follow-up, it is likely that a non-
negligible proportion of our stable MCI over 5 years is still affected by
AD and presented evident atrophies at baseline, as suggested by the fact
that we obtained a significant number of false positives. In this context,












































Fig. 5. Percentage of correctly classified MCI converters for each marker as a function of conversion time. N indicates the number of conversions per year.
Table 3
Summary of MRI machine learning algorithms reviewed in (Rathore et al., 2017). p stands for converter MCI, s for stable MCI, CV indicates that cross-validation was
used for evaluation.
Study Training sample size Evaluation method Follow-up time (years) AUC
Misra et al. (2009) (Misra et al., 2009) 27p/76 s CV Variable (Mean=2 years) 77%
Liu et al. (2013) (Liu et al., 2013) 97p/93 s CV 3 72%
Eskildsen et al. (2013) (Eskildsen et al., 2013) 128p/227 s CV Variable (Mean=1.5 years) 68%
Min et al. (2014) (Min et al., 2014) 98AD/128NC CV (117p/117 s) Not reported 67%
Liu et al. (2015) (Liu et al., 2015) 117p/117 s CV Not reported 81%
Tang et al. (2015) (Tang et al., 2015) 175AD/210NC CV (135p/87 s)) 3 74%
Chincarini et al. (2011) (Chincarini et al., 2011) 144AD/189NC Independent set (136p/166 s) 2 74%
Wee et al. (2013) (Wee et al., 2013) 45p/56 s Repeated hold-out (44p/55 s) 3 84%
Sorensen et al. (2016) (Sorensen et al., 2016) 101AD/169NC Independent set (93p/140 s) 2 74%
Hippocampus+Entorhinal Cortex 230AD/230NC Independent set (133p/198 s) 2 73%
Hippocampus+Entorhinal Cortex 230AD/230NC Independent set (156p/152 s) 3 76%
Hippocampus+Entorhinal Cortex 230AD/230NC Independent set (177p/84 s) 5 84%
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and given the lack of data with long follow-ups, the usually abandoned
strategy of using NC vs. AD for training might be more adequate than
what was expected.
This study had some limitations. ADNI1 and ADNI2 used MRI
scanners with different field strengths, so combining results from both
studies might have influenced our results. However, our models were
fitted separately for ADNI1 and ADNI2 data, contributing to better
control of bias and generalizability. The heterogeneous protocols in
ADNI1 and ADNI2, combining different sequences, are sources of
variability whose assessment is beyond the scope of this work but that
definitively need to be addressed in future studies. Since we focused on
patients with long follow-up, our results might suffer from survivor
bias. Nevertheless, Subanalysis 2, performed on the patients that did
not reach the follow-up time, supported our conclusions, so we con-
clude that this source of bias is not significantly affecting our conclu-
sions.
5. Conclusions
In conclusion, we found that MRI was highly predictive in mid-term
pMCI, correctly classifying most of them. As a consequence, specificity
and discriminative power increased at 5-year follow-up, outperforming
complex machine learning approaches of incipient AD detection with
shorter follow-up times.
The unexpected good performance of MRI in the mid-term revealed
the problem that an insufficient follow-up time may create for machine
learning algorithms, given that these algorithms regard as non-diseased
an important proportion of patients actually affected by AD and with
evident atrophies. This may result in poor performance and lack of
generalizability, as well as in non-interpretability of algorithm predic-
tions. If sample enrichment for short-term clinical trials is required,
other variables that predict short-term conversion must be included
along with MRI.
A short follow-up might be also problematic when deriving bio-
marker cut-points from MCI samples, especially for those representing
the early stages of the disease.
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